Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules
RGH-MD-20
Phase 3 small_molecule active
Quick answer
Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules for Adolescent Patients (13 to 17 years of age) with Schizophrenia is a Phase 3 program (small_molecule) at Gedeon Richter Plc. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gedeon Richter Plc.
- Indication
- Adolescent Patients (13 to 17 years of age) with Schizophrenia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active